Shinpoong Pharmaceutical Co., Ltd.

As of June 30, 2026, Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.16, indicating elevated leverage, while an interest coverage ratio of 4.62 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting posted a negative return on equity (ROE) of -0.31, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -116.49, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -0.23, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -125.41, pointing to unprofitable operations over the period. The company generates approximately 298.09M in revenue per employee across its workforce of 802.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.25 indicates how many times Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting recorded 752.17M in income tax expense. That works out to an effective tax rate of 13,304.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.65M, leaving -815.28M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting's stock has declined approximately 42.40% over the past 52 weeks. The 50-day moving average sits at 14,080.60, while the 200-day moving average is 16,222.15.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 14.01B, while operating income came in at 2.69B.

As of June 30, 2026, Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting holds 72.31B in cash and equivalents against 53.28B in total debt, resulting in a net debt position of 4.31B. Total book value stands at 276.08B, with working capital of 137.88B providing operational flexibility.

Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting produced 17.57B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting posted a gross margin of 42.71, reflecting its pricing power and cost economics. The operating margin of 1.13 and net profit margin of -0.34 provide insight into operational efficiency.

Shinpoong Pharmaceutical Co Ltd Pfd Non-Voting's most recent stock split took place on May 4, 2011 with a 1:10 split ratio.